Zomedica (ZOM) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 12, 2021
Cover [Abstract]
Entity Registrant Name	Zomedica Corp
Entity Central Index Key	0001684144
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity Ex Transition Period	true
Entity Common Stock Shares Outstanding		979,894,668
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38298
Entity Incorporation State Country Code	Z4
Entity Address Address Line 1	100 Phoenix Drive
Entity Address Address Line 2	Suite 125
Entity Address City Or Town	Ann Arbor
Entity Address State Or Province	MI
Entity Address Postal Zip Code	48108
City Area Code	734
Local Phone Number	369-2555
Security 12b Title	Common Shares, without par value
Trading Symbol	ZOM
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 271,411,043	$ 61,991,703
Inventory	1,423,923	0
Prepaid expenses and deposits	1,633,846	1,727,814
Trade receivables	6,938	0
Other receivables	258,359	146,207
Total current assets	274,734,109	63,865,724
Prepaid expenses and deposits	168,020	13,924
Property and equipment, net	706,266	583,007
Right-of-use asset	1,419,790	1,318,716
Intangible assets, net	473,966	362,663
Total assets	277,502,151	66,144,034
Current liabilities
Accounts payable and accrued liabilities	4,464,874	1,248,628
Current portion of debt obligations	0	527,360
Current portion of lease obligations	407,278	252,788
Total current liabilities	4,872,152	2,028,776
Lease obligations	1,069,687	1,087,998
Total liabilities	5,941,839	3,116,774
Mezzanine equity:
Series 1 preferred shares, no par value;20 shares authorized0 and 12 Series 1 preferred shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively		11,961,397
Shareholders' equity
Unlimited common shares, no par value;979,738,168 and 642,036,228 issued and outstanding at September 30, 2021 and December 31, 2020, respectively	380,928,831	104,783,612
Common shares subscribed	0	459,600
Additional paid-in capital	6,732,887	14,792,276
Accumulated deficit	(116,101,406)	(68,969,625)
Total shareholders' equity	271,560,312	51,065,863
Total liabilities, mezzanine equity and shareholders' equity	$ 277,502,151	$ 66,144,034

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, issued (in shares)	979,738,168	642,036,228
Capital stock, outstanding (in shares)	979,738,168	642,036,228
Statement of Financial Position [Abstract]
Mezzanine equity, par value (in dollars per share)	$ 0	$ 0
Mezzanine equity, shares authorized (in shares)	20	20
Mezzanine equity, shares issued (in shares)	0	12
Mezzanine equity, shares outstanding (in shares)	0	12

Condensed Consolidated Statemen

Condensed Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Net revenue	$ 22,514	$ 0	$ 52,331	$ 0
Cost of revenue	17,899	0	59,433	0
Gross profit	4,615	0	(7,102)	0
Expenses
Research and development	288,453	2,702,103	1,008,083	7,205,674
Selling, general and administrative	6,124,382	2,298,330	14,593,952	5,430,812
Loss from operations	(6,408,220)	(5,000,433)	(15,609,137)	(12,636,486)
Interest income	(94,302)	(21,238)	(261,556)	(21,566)
Interest expense	0	0	6,054	732
Loss on disposal of assets	26,760	0	269,707	128,931
Gain on extinguishment of debt	0	0	(533,414)	0
Other gains	(600)	(1,963)	(2,481)	(7,463)
Foreign exchange loss	5,609	2,743	5,731	1,462
Loss before income taxes	(6,345,687)	(4,979,975)	(15,093,178)	(12,738,582)
Net loss and comprehensive loss	$ (6,345,687)	$ (4,979,975)	$ (15,093,178)	$ (12,738,582)
Weighted average number of common shares - basic and diluted	978,494,076	550,541,878	948,664,410	291,314,002
Loss per share - basic and diluted (Note 18)	$ (0.01)	$ (0.01)	$ (0.05)	$ (0.04)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Total	Common Stock	Common Stock Subscribed	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Series I Preferred Stock
Balance, shares at Dec. 31, 2019						12
Balance, amount at Dec. 31, 2019	$ 2,095,459	$ 38,566,820	$ 0	$ 3,625,083	$ (52,057,841)	$ 11,961,397
Stock, warrants and pre-funded warrants issuance for financing, shares						108,038,398
Stock, warrants and pre-funded warrants issuance for financing, amount	56,496,283	32,275,266	0	24,221,017	0
Stock issuance costs, amount	(5,107,615)	(2,979,594)	0	(2,128,021)	0
Placement agent warrants, shares						337,830,001
Placement agent warrants, amount	0	(154,767)	0	154,767	0
Stock-based compensation	478,835	0	0	478,835
Stock issued from exercise of warrants and prefunded warrants, amount	12,155,409	20,250,412	0	(8,095,003)	0
Net loss	(12,738,582)	0	0	0	(12,738,582)
Balance, amount at Sep. 30, 2020	87,958,137
Balance, shares at Jun. 30, 2020						12
Balance, amount at Jun. 30, 2020	29,578,961	67,328,922	1,465,500	8,639,590	(59,816,448)	$ 11,961,397
Stock, warrants and pre-funded warrants issuance for financing, shares						564,051,438
Stock, warrants and pre-funded warrants issuance for financing, amount	28,532,000	16,290,941	(1,465,500)	13,706,559	0
Stock issuance costs, amount	(2,268,215)	(1,224,218)	0	(1,043,997)	0
Placement agent warrants, shares						361,039,946
Placement agent warrants, amount	0	0	0	0	0
Stock-based compensation	187,969	0	0	187,969	0
Stock issued from exercise of warrants and prefunded warrants, amount	2,329,049	5,562,492	0	(3,233,443)	0
Net loss	(4,979,975)	0	0	0	(4,979,975)
Stock issuance costs, shares						12
Balance, amount at Sep. 30, 2020	87,958,137
Balance, amount at Dec. 31, 2020	51,065,863	104,783,612	459,600	14,792,276	(68,969,625)	$ 0
Stock issuance costs, amount	(14,280,914)	(14,280,914)	0	0	0	0
Stock-based compensation	4,502,597	0	0	4,502,597	0	0
Net loss	(15,093,178)	0	0	0	(15,093,178)	$ 0
Stock issuance for financing, shares						642,036,228
Stock issuance for financing, amount	199,525,000	199,525,000	0	0	0	$ 0
Stock issued from warrant exercises, amount	$ 32,111,537	44,082,183	(459,600)	(11,511,046)	0	0
Stock issued from stock option exercises, shares	7,017,776
Stock issued from stock option exercises, amount	$ 1,768,010	2,818,950	0	(1,050,940)	0	$ 0
Preferred share exchange						24,719,101
Preferred share exchange, amount	11,961,397	44,000,000	0	0	(32,038,603)	$ 0
Balance, amount at Sep. 30, 2021	271,560,312
Balance, shares at Jun. 30, 2021						977,950,993
Balance, amount at Jun. 30, 2021	276,068,013	380,222,091	0	5,601,641	(109,755,719)	$ 0
Stock-based compensation	1,437,778	0	0	1,437,778	0	0
Net loss	$ (6,345,687)	0	0	0	(6,345,687)	0
Stock issued from stock option exercises, shares	1,787,175
Stock issued from stock option exercises, amount	$ 400,208	$ 706,740	$ 0	$ (306,532)	$ 0	$ 0
Balance, amount at Sep. 30, 2021	$ 271,560,312

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (15,093,178)	$ (12,738,582)
Adjustments for
Depreciation	175,168	232,475
Amortization - intangible assets	136,200	177,873
Loss on disposal of property and equipment	247,753	69,834
Loss on other assets	5,323	59,097
Gain on extinguishment of debt	(533,414)	0
Stock-based compensation	4,502,597	478,835
Non-cash portion of rent expense	35,838	16,051
Change in non-cash operating working capital
Purchased inventory	(1,875,423)	0
Prepaid expenses and deposits	(61,004)	(1,003,091)
Trade receivable	(6,938)	0
Other receivables	(122,972)	(61,651)
Accounts payable and accrued liabilities	3,216,246	(787,124)
Net cash used in operating activities	(9,373,804)	(13,556,283)
Cash flows from investing activities:
Cash from sale of property and equipment	225	5,400
Investment in intangibles	(245,560)	0
Investment in property and equipment	(96,964)	(613)
Cash from lease cancellation or modification	0	1,002,113
Net cash (used in) provided by investing activities	(342,299)	1,006,900
Cash flows from financing activities:
Proceeds from issuance of common shares, warrants and pre-funded warrants	199,525,000	56,496,283
Cash received from warrant exercises	32,111,537	12,155,409
Cash received from stock option exercises	1,768,010	0
Cash received from shares to be issued	0	0
Cash paid on stock issuance costs	(14,269,104)	(5,107,615)
Cash received for government loan	0	527,360
Net cash provided by financing activities	219,135,443	64,071,437
Increase in cash and cash equivalents	209,419,340	51,522,054
Cash and cash equivalents, beginning of period	61,991,703	510,586
Cash and cash equivalents, end of period	271,411,043	52,032,640
Noncash investing and financing activities
Transfer of inventory into property and equipment	451,500	0
Deferred financing fees charged to stock issuance costs	11,810	0
Account receivable recorded in intercompany account	(990)	0
Net equity effect of preferred share exchange	(11,961,397)	0
Supplemental cash flow information:
Interest paid	0	651
Interest received	$ 228,881	$ 14,347

Note 1 - Nature of Operations

Note 1 - Nature of Operations	9 Months Ended
	Sep. 30, 2021
Note 1 - Nature of Operations
1. Nature of operations	1. Nature of operations The Company is a veterinary health company creating point-of-care diagnostics products for dogs and cats, that focuses on the needs of the veterinarians themselves. The impact of the novel strain of coronavirus (“COVID-19”) The outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, has resulted in the World Health Organization declaring this virus a global pandemic in March 2020. Governments around the world have enacted emergency measures to combat the spread of the virus. These measures include the implementation of travel bans, self-imposed quarantine periods and social distancing. The closure of businesses has caused material disruption to businesses resulting in an economic slowdown. Governments and central banks have responded with significant monetary and fiscal interventions designed to stabilize the financial markets. The COVID-19 pandemic materially and adversely affected the development and commercialization of our TRUFORMA® platform and the initial five assays. In response to the pandemic, our development partner had reduced the number of employees working in its facilities for a period of time which has delayed the completion of the verification of the five initial TRUFORMA® assays and the manufacturing of commercial quantities of the TRUFORMA® platform and the related assays. Veterinary hospitals and clinics that had agreed to participate in the validation of our initial TRUFORMA® assays either shut down for a period of time or limited their operations to those involving only life-threatening conditions, which we have mitigated to a certain extent with our recent ability to successfully complete remote installations. Potential customers have at times restricted access to their facilities which has affected and may continue to affect our ability to perform on-site demonstrations and other marketing activities. The extent to which the COVID-19 pandemic may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the spread and severity of COVID-19, and the effectiveness of governmental actions in response to the pandemic.

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	9 Months Ended
	Sep. 30, 2021
Note 1 - Nature of Operations
2. Basis of preparation	2. Basis of preparation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for the presentation of interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited financial statements do not include all the information and footnotes necessary for a comprehensive presentation of the financial position, results of operations and cash flows for the periods presented. In the opinion of management, the unaudited financial statements include all the normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the three and nine months ended September 30, 2021, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. These unaudited financial statements should be read in combination with the other Notes in this section; “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing in Item 2; and the Consolidated Financial Statements, including the Notes to the Consolidated Financial Statements, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Consolidated Balance Sheet as of December 31, 2020, was derived from audited financial statements.

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Note 3 - Significant Accounting Policies
3. Significant accounting policies	3. Significant accounting policies Estimates and assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Inventories Inventories are stated at the lower of cost or net realizable value. The Company utilizes specific identification to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Intangible Assets Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life. Revenue recognition The Company enters into agreements which may contain multiple promises where customers purchase products, services or a combination thereof. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires judgment. We determine the transaction price for a contract based on the total consideration we expect to receive in exchange for the transferred goods or services. The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company’s contracts with customers are generally comprised of purchase orders for the sale of the point of care diagnostic instrument, consumable products, and warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The warranties are also a separate performance obligation, whereby revenue is recognized over time. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority. Accounts receivable are recorded at net realizable value and have payment terms of 30 days. Cost of revenue Cost of goods sold consists of materials, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of goods sold. Comparative figures Certain prior year amounts have been reclassified to conform to the current year presentation. The change in presentation had no effect on the reported results of operations. Adjustments have been made to the consolidated balance sheets and consolidated statements of loss and comprehensive loss for three and six months ended September 30, 2020. These changes in classification do not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.

Note 4 - Prepaid Expenses, Depo

Note 4 - Prepaid Expenses, Deposits and Deferred Financing Costs	9 Months Ended
	Sep. 30, 2021
Note 4 - Prepaid Expenses, Deposits and Deferred Financing Costs
4. Prepaid expenses, deposits, and deferred financing costs	4. Prepaid expenses, deposits, and deferred financing costs September 30, December 31, 2021 2020 Deposits (i) $ 1,256,094 $ 1,469,043 Prepaid marketing 64,300 26,330 Prepaid insurance 380,254 184,154 Other (ii) 101,218 62,211 Total $ 1,801,866 $ 1,741,738 (i) Deposits include payments made to vendors in advance and are primarily associated with inventory, warranties, and research activity. As of September 30, 2021, and December 31, 2020, the Company classified $168,020 and $13,924 as a non-current asset, with the remainder classified as a current asset in the consolidated balance sheets. (ii) Other is comprised of deferred financing costs, subscription payments, utilities, travel costs, and software licensing. As of September 30, 2021, and December 31, 2020, the Company classified all amounts as a current asset in the consolidated balance sheets.

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended
	Sep. 30, 2021
Note 5 - Property and Equipment
5. Property and equipment	5. Property and equipment September 30, December 31, 2021 2020 Computer equipment $ 901,379 $ 364,165 Furniture and equipment 110,244 121,281 Laboratory equipment 225,330 234,087 Leasehold improvements 275,149 571,460 1,512,102 1,290,993 Accumulated depreciation and amortization 805,836 707,986 Net property and equipment $ 706,266 $ 583,007 Depreciation expense for the three months ended September 30, 2021 and 2020 was $60,445 and $78,200, respectively and for the nine months ended September 30, 2021 and 2020 was $175,168 and $232,475, respectively.

Note 6 - Intangible Assets

Note 6 - Intangible Assets	9 Months Ended
	Sep. 30, 2021
Note 6 - Intangible Assets
6. Intangible assets	6. Intangible assets September 30, December 31, 2021 2020 Computer software 28,097 $ 22,882 Trademarks 16,236 16,236 Website 755,968 513,680 800,301 552,798 Accumulated amortization 326,335 190,135 Net intangibles $ 473,966 $ 362,663 Amortization expense for the three months ended September 30, 2021 and 2020 was $46,732 and $45,399, respectively and for the nine months ended September 30, 2021 and 2020 was $136,200 and $135,425, respectively.

Note 7 - Leases

Note 7 - Leases	9 Months Ended
	Sep. 30, 2021
Note 7 - Leases
7. Leases	7. Leases On February 1, 2020, the Company cancelled its existing lease with Wickfield Phoenix LLC. and entered a new lease. The new lease period was for 60 months, commencing on February 1, 2020, and ending on January 31, 2025, with a monthly rent payment of $32,452 escalating to $36,525 over the lease period. Upon cancellation of the previous existing lease, the Company received a refund of prepaid rent in the amount of $1,002,113. The carrying value of the right of use asset was $1,061,210 upon cancellation. The Company recorded a loss on right-of-use asset of $59,097 during the three months ended March 31, 2020 in the consolidated statements of comprehensive loss. On February 1, 2020, the Company recorded a right-of-use asset and a corresponding lease liability in the amount of $1,553,611 using the Company’s incremental borrowing rate of 12%. On February 1, 2021, the Company downsized its office space and modified its existing lease with Wickfield Phoenix LLC. The new lease period was for 48 months, commencing on February 1, 2021, and ending on January 31, 2025, with a monthly rent payment of $12,039 for the first two months and escalating to $30,911 over the lease period. The carrying value of the right of use asset was $1,258,263 upon modification. The Company recorded a gain on right-of-use asset of $731 during the three months ended March 31, 2021 in the consolidated statements of comprehensive loss. On February 1, 2021, the Company recorded a right-of-use asset and a corresponding lease liability in the amount of $1,281,609 using the Company’s incremental borrowing rate of 3.95%. On September 15, 2021, the Company entered into an additional lease with Wickfield Phoenix LLC for warehousing space. The new lease period is for 41 months, commencing on September 15, 2021, and ending on January 31, 2025, with a monthly rent payment of recorded a right-of-use asset and a corresponding lease liability in the amount of $4,580 for the first month and escalating to $10,009 over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $365,840 using the Company’s incremental borrowing rate of 3.95%. During the three and nine months ended September 30, 2021, the Company recognized $93,980 and $270,554 in rent expense, $3,882 of the expense was for common area maintenance charges, with $31,605 and $69,403 recorded in research and development expenses, respectively and $62,375 and $201,151 recorded in general and administrative expense, respectively in the consolidated statements of comprehensive loss. During the three and nine months ended September 30, 2020, the Company recognized $103,375 and $279,997 in rent expense with $17,229 and $56,221 recorded in research and development expenses and $86,146 and $223,776 recorded in general and administrative expense, respectively in the consolidated statements of comprehensive loss. September 30, 2021 December 31, 2020 Right-of-use asset Cost Aggregate lease commitments $ 1,778,798 $ 2,067,505 Less: impact of present value and lease modification (154,695 ) (513,894 ) Balance 1,624,103 1,553,611 Reduction in right-of-use asset Straight line amortization 232,214 379,043 Interest (27,901 ) (144,148 ) Balance 204,313 234,895 Net book value $ 1,419,790 $ 1,318,716 Lease liabilities Additions $ 1,647,449 $ 1,553,611 Payments (198,385 ) (356,972 ) Interest 27,901 144,147 Total lease liabilities $ 1,476,965 $ 1,340,786 Current portion of lease liabilities 407,278 252,788 Long term portion of lease liabilities 1,069,687 1,087,998 Total lease liabilities $ 1,476,965 $ 1,340,786 Total remaining undiscounted lease liabilities related to the above lease are as follows: 2021 - remainder balance $ 112,342 $ 400,133 2022 461,727 412,137 2023 475,579 424,501 2024 489,845 437,236 2025 40,920 36,526 Total $ 1,580,413 $ 1,710,533

Note 8 - Loan Arrangements

Note 8 - Loan Arrangements	9 Months Ended
	Sep. 30, 2021
Note 8 - Loan Arrangements
8. Loan arrangements	8. Loan arrangements On October 18, 2017, the Company entered into a loan arrangement with a shareholder of the Company, pursuant to which such shareholder has agreed to provide a loan facility to the Company, whereby the Company may borrow up to $5,000,000, with the proceeds to be used for working capital and general corporate purposes. The term of the loan facility is five (5) years, with principal and interest payments being due only at the time of maturity. Under the loan agreement, the Company may borrow in one or more advances, provided however that a minimum amount of $250,000 must be borrowed at any one time and not more than two advances may occur per month. Interest shall accrue at a rate of fourteen percent (14%) per annum, payable upon maturity. As of September 30, 2021, no amounts have been borrowed. The Coronavirus Aid, Relief, and Economic Security Act, or (“CARES”) Act, was signed into law on March 27, 2020, and provides over $2.0 trillion in emergency economic relief to individuals and businesses impacted by the COVID-19 pandemic. The CARES Act authorized the Small Business Administration to temporarily guarantee loans under a new loan program called the Paycheck Protection Program (the “Program”). The Program provides for 100% federally guaranteed loans to small businesses to allow employers to keep workers employed and maintain payroll during the pandemic and economic downturn. Under the Program, qualified companies are eligible for a loan in an amount equal to the lesser of $10 million or 2.5x the business’s average monthly payroll. Collateral or guarantor support is not required for the loan. Under the Program, the borrower is eligible for loan forgiveness up to the amount the borrower spends on certain eligible costs during the 8-week period beginning on the date the proceeds were received on the loan. Eligible costs under the Program include payroll costs, interest on mortgage obligations incurred before the covered period, rent on leasing agreements and utility services. The amount of loan forgiveness is reduced if there is a reduction in the number of employees or a reduction of greater than 25% in wages paid to employees. Under the Program, proceeds that are not forgiven convert to a loan bearing interest at a fixed rate of 1% payable in 18 equal monthly installments commencing after the forgiveness period. The Program was subsequently amended to allow the borrower to use an extended forgiveness period of 24 weeks beginning on the date the proceeds were received on the loan and to extend the repayment period to 54 months commencing after the 24-week forgiveness period. In April of 2020, the Company received $527,360 under the program. The receipt was reported as a current liability and accounted for as a loan. The Company was granted forgiveness on June 13, 2021 and recorded a gain on the extinguishment of debt for $533,414, inclusive of $6,054 in accrued interest.

Note 9 - Preferred Stock

Note 9 - Preferred Stock	9 Months Ended
	Sep. 30, 2021
Note 9 - Preferred Stock
9. Preferred shares	9. Preferred shares The Company is authorized to issue up to 20 shares of its Series 1 Preferred Shares, all without par value, and each having a stated value of $1,000,000. The Series 1 Preferred Shares do not have voting rights except to the extent required by applicable law and are not convertible into the Company’s common shares. Holders of the Series 1 Preferred Shares will not be entitled to dividends but, in lieu thereof, will receive Net Sales Returns (“Net Sales Returns” is defined as annual payments equal to 9 percent of net sales) until such time as the holders have received total Net Sales Returns equal to 9 times the aggregate stated value of the outstanding Series 1 Preferred Shares. The Company will have the right to redeem the outstanding Series 1 Preferred Shares at any time at a redemption price equal to 9 times the aggregate stated value of the Series 1 Preferred Shares outstanding less the aggregate amount of the Net Sales Returns paid (the “Redemption Amount”). Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series 1 Preferred Shares will be entitled to a liquidation preference equal to the stated value of the Series 1 Preferred Shares less the Net Sales Returns paid on the Series 1 Preferred Shares. In the event of a fundamental transaction (defined to include an amalgamation, merger or other business combination transaction involving our company in which the shareholders do not have the right to cast more than 50% of the votes that may be cast for the election of directors, or a sale, lease or other disposition of the properties and/or assets of our company as an entirety or substantially as an entirety to a third party), the holders of the Series 1 Preferred Shares will be entitled to receive consideration for their Series 1 Preferred Shares equal to a multiple of the stated value of the Series 1 Preferred Shares ranging from 5.0 to 9.0 depending on the timing of the fundamental transaction, subject to a cap equal to the redemption amount. Issued and outstanding preferred stock: Number of Preferred preferred stock stock amount Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 11,961,397 Stock exchanged (12 ) (11,961,397 ) Balance at September 30, 2021 - $ - The Company exchanged the issued and outstanding shares of its Series 1 Preferred Shares on March 7, 2021, for 24,719,101 of common shares valued at $44,000,000. The difference between the carrying value of the preferred shares and the fair value of the common shares exchanged of $32,038,603 was charged to accumulated deficit.

Note 10 - Common Stock

Note 10 - Common Stock	9 Months Ended
	Sep. 30, 2021
Note 10 - Common Stock
10. Common shares	10. Common shares (i) On February 14, 2020, the Company completed a registered direct offering (“RDO”) of its common shares and a simultaneous private placement of its warrants (“Series A Warrants”) in a fixed combination of one common share and a Series A Warrant to purchase one common share, resulting in the sale of 20,833,334 common shares and Series A Warrants to purchase 20,833,334 common shares at a combined offering price of $0.12 per share and related Series A Warrant. Each Series A Warrant has an exercise price of $0.20 per share, is exercisable six months after issuance and has a term of 5.5 years. The Company also issued warrants to the placement agents to purchase 1,041,667 common shares at an exercise price of $0.15 per share (“Placement Agent Warrants”), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 20,833,334 common shares, 20,833,334 Series A Warrants, and an additional 1,041,667 Series A Placement Agent Warrants. The Company raised $2,500,000 in gross proceeds as part of the RDO. The Company recorded $1,705,655 as the value of common shares under common shares and $794,345 as the value of Series A Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 were $348,220. These direct costs were recorded as an offset against the statement of shareholders’ equity with $238,217 being recorded under common shares and $110,003 being recorded under additional paid-in-capital. The Company also recorded the value of the Series A Placement Agent Warrants in the amount of $52,496 as an offset against the statement of shareholders’ equity with $35,816 being recorded under common shares and $16,680 being recorded under additional paid-in-capital. (ii) On April 9, 2020, the Company completed a confidentially marketed public offering (“CMPO”) of its common shares and warrants (“Series B Warrants”) of 33,333,334 common shares and warrants to purchase up to 16,666,667 common shares. The securities were sold in a fixed combination of one common share and 0.5 of a Series B Warrant at a combined offering price of $0.12 per share and accompanying warrant. Each whole warrant is exercisable immediately for one common share after issuance, at an exercise price of $0.15 per share and has a term of 5 years. The Company also issued warrants to the placement agents to purchase 1,666,667 common shares at an exercise price of $0.15 per share (“Series B Placement Agent Warrants”), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 33,333,334 common shares,16,666,667 Series B Warrants in addition to 1,666,667 Series B Placement Agent Warrants. The Company raised $4,000,000 in gross proceeds in the CMPO. The Company recorded $2,942,248 as the value of common shares under common stock and $1,057,752 as the value of Series B Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares and warrants issued in April were $582,977. These direct costs were recorded as an offset against the statement of shareholders’ equity with $428,283 being recorded under capital stock and $154,694 being recorded under additional paid-in-capital. The Company also recorded the value of the Series B Placement Agent Warrants in the amount of $161,714 as an offset against the statement of shareholders’ equity with $118,951 being recorded under capital stock and $42,763 being recorded under additional paid-in-capital. (iii) On May 29, 2020 the Company completed a public offering of its common shares or common share equivalents (“Series C pre-funded warrants”), and warrants (“Series C Warrants”) in a fixed combination of one common share or Series C pre-funded warrant, and a Series C Warrant to purchase one common share, resulting in the sale of 121,163,333 common shares, 12,170,000 pre-funded warrants, and Series C Warrants to purchase 133,333,333 common shares at a combined offering price of $0.15 per share for the common shares and related Series C Warrant, or a combined offering price of $0.1499 per pre-funded warrant and related Series C warrant. Each Series C pre-funded warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series C Warrant has an exercise price of $0.15 per share, is exercisable immediately after issuance and has a term of 2 years. The Company raised $19,998,783 in gross proceeds as part of the public offering. The Company recorded $11,336,422 as the value of common shares under common stock, $1,080,289 as the value of the pre-funded warrants and $7,582,072 as the value of Series C Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares, Series C pre-funded warrants and Series C Warrants issued in May were $1,908,202. These direct costs were recorded as an offset against the statement of shareholders’ equity with $1,088,876 being recorded under capital stock and $819,327 being recorded under additional paid-in-capital. (iv) On July 7, 2020 the Company completed a public offering of its common shares or common share equivalents (“Series D Pre-Funded Warrants”), and warrants (“Series D Warrants”) in a fixed combination of one common share or Series D Pre-Funded warrant, and a Series D Warrant to purchase one common share, resulting in the sale of 162,500,000 common shares, 25,000,000 Series D Pre-Funded Warrants, and Series D Warrants to purchase 187,500,000 common shares at a combined offering price of $0.16 per share for the common shares and related Series D Warrant, or a combined offering price of $0.1599 per Series D Pre-Funded warrant and related Series D Warrant. Each Series D Pre-Funded warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series D Warrant has an exercise price of $0.16 per share, is exercisable immediately after issuance, and has a term of 2 years. The Company raised $29,997,500 in gross proceeds as part of the public offering. The Company recorded $16,290,941 as the value of common shares under common stock, $2,329,983 as the value of the Series D Pre-Funded Warrants and $11,376,575 as the value of the Series D Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares, Series D Pre-Funded Warrants and Series D Warrants issued in July 2020 were $2,268,215. These direct costs were recorded as an offset against the statement of shareholders’ equity with $1,224,218 being recorded under capital stock and $1,043,997 being recorded under additional paid-in-capital. (v) All Series C pre-funded warrants were exercised in June 2020. Upon exercise the value of the warrant exercise was based on the one-day VWAP of the Company stock the day before the exercise request date. The cashless exercise option resulted in the issuance of 12,162,492 shares. (vi) On February 8, 2021, the Company completed a sale of 91,315,790 common shares at an offering price of $1.90 per share. The Company also granted the underwriter a 30-day option to purchase up to 13,697,368 additional common shares at the public offering price. The Company raised $199,525,000 in gross proceeds as part of the offering. The Company recorded $199,525,000 as the value of common shares under common shares. The direct cash costs related to the issuance of the common shares and warrants issued in February 2021 were $14,2980,914. These direct costs were recorded as an offset against the statement of shareholders’ equity with the entirety recorded under common shares.

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Note 11 - Stock-based Compensation
11. Stock-based compensation	11. Stock-based compensation During the three and nine months ended September 30, 2021, the Company issued stock options to purchase an aggregate of 2,900,000 and 12,100,000 common shares. The options vest over a period of four years and have an expiration period of ten years. During the three and nine months ended September 30, 2021, 1,787,175, and 7,017,776 options were exercised, and the Company received $400,208 and $1,768,011 in cash receipts and reclassified $306,532 and $1,050,940 of additional paid in capital to common stock due to the exercise of stock options. During the three and nine months ended September 30, 2020, the Company issued stock options to purchase an aggregate of 515,000 and 7,571,000 common shares. The options vest over a period of four years and have an expiration period of five years. During the three and nine months ended September 30, 2020, no stock options were exercised. The Company recorded $1,437,778 and $4,502,597 of stock-based compensation for the three and nine months ended September 30, 2021. The Company recorded $187,969 and $478,835 of stock-based compensation for the three and nine months ended September 30, 2020. The continuity of stock options are as follows: Number of Options Weighted Avg Exercise Price Balance at December 31, 2020 39,604,515 $ 0.36 Stock options granted 12,100,000 $ 0.86 Stock options exercised 7,017,776 $ 0.25 Unvested stock options forfeited 1,670,000 $ 0.64 Vested stock options exprired 4,034,015 $ 1.52 Balance at September 30, 2021 38,982,724 $ 0.40 Vested at September 30, 2021 9,152,474 $ 0.28 As of September 30, 2021, details of the issued and outstanding stock options were as follows: Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) March 14, 2020 0.19 3,028,557 1,675,807 1,352,750 3.45 July 9, 2020 0.18 175,000 87,500 87,500 3.78 August 25, 2020 0.13 20,000 - 20,000 3.90 September 29, 2020 0.11 225,000 225,000 - 4.00 October 1, 2020 0.11 266,667 41,667 225,000 4.01 October 20, 2020 0.09 25,000 10,000 15,000 4.06 December 31, 2020 0.23 24,142,500 6,762,500 17,380,000 4.25 February 26, 2021 1.87 600,000 150,000 450,000 4.41 March 1, 2021 2.06 200,000 50,000 150,000 4.42 March 8, 2021 1.88 200,000 50,000 150,000 4.44 March 15, 2021 2.49 200,000 50,000 150,000 4.46 May 12, 2021 0.78 3,800,000 - 3,800,000 4.62 May 14, 2021 0.75 3,200,000 50,000 3,150,000 4.62 August 11, 2021 0.57 1,300,000 - 1,300,000 4.87 August 18, 2021 0.50 200,000 - 200,000 4.88 August 23, 2021 0.50 100,000 - 100,000 4.90 September 13,2021 0.57 800,000 - 800,000 4.96 September 27,2021 0.54 500,000 - 500,000 4.99 Balance at September 30, 2021 38,982,724 9,152,474 29,830,250 The Company calculates volatility of stock-based compensation using the historical price of the Company’s stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. The fair value of options granted during the three and nine months ended September 30, 2021 was estimated using the Black-Scholes option pricing model to determine the fair value of options granted using the following assumptions: February 26, 2021 March 1, 2021 March 8, 2021 March 15, 2021 Volatility 117 % 117 % 117 % 117 % Risk-free interest rate 0.95 % 0.92 % 1.07 % 1.06 % Expected life 10 years 10 years 10 years 10 years Dividend yield 0 % 0 % 0 % 0 % Common share price $ 1.87 $ 2.06 $ 1.88 $ 2.49 Strike price $ 1.87 $ 2.06 $ 1.88 $ 2.49 Forfeiture rate zero zero zero zero May 12, 2021 August 11, 2021 August 23, 2021 September 13, 2021 Volatility 118 % 116 % 116 % 116 % Risk-free interest rate 1.11 % 0.96 % 0.92 % 0.96 % Expected life 6.21 - 6.22 Years 6.18 - 6.25 6.25 6.25 Dividend yield 0 % 0 % 0 % 0 % Common share price $ 0.78 $ 0.56 $ 0.50 $ 0.57 Strike price $ 0.78 $ 0.57 $ 0.50 $ 0.57 Forfeiture rate zero zero zero zero September 27, 2021 Volatility 116 % Risk-free interest rate 1.14 % Expected life 6.25 Dividend yield 0 % Common share price $ 0.54 Strike price $ 0.54 Forfeiture rate zero

Note 12 - Warrants

Note 12 - Warrants	9 Months Ended
	Sep. 30, 2021
Note 12 - Warrants
12. Warrants	12. Warrants In connection with the February 14, 2020 registered direct offering, the Company issued 20,833,334 five and one half-year Series A warrants to purchase one share of common stock at an exercise price of $.20. The Company also issued 1,041,667 warrants to purchase a share of common stock at an exercise price of $0.15 per share to the placement agents. In connection with the April 9, 2020 CMPO, the Company issued 16,666,667 five-year Series B Warrants to purchase one common share at an exercise price of $0.15. The Company also issued 1,666,667 Placement Agent Warrants to purchase one common share at an exercise price of $0.15 per share. In connection with the May 29, 2020 public offering, the Company issued 133,333,333 two-year Series C Warrants to purchase one common share at an exercise price of $0.15. The Company also issued 12,170,000 Series C Pre-Funded Warrants to purchase common shares at an exercise price of $0.0001 on a cashless exercise basis. As of December 31, 2020, all of the Series C Pre-Funded Warrants have been exercised. In connection with the July 7, 2020 public offering, the Company issued 187,500,000 two-year Series D Warrants to purchase one common share at an exercise price of $0.16. The Company also issued 25,000,000 Series D Pre-Funded Warrants to purchase common shares at an exercise price of $0.0001 on a cashless exercise basis. As of December 31, 2020, all of the Series D Pre-Funded Warrants have been exercised. As of September 30, 2021, details of the outstanding warrants were as follows: Original Issue date Exercise Price Warrants Outstanding Weighted Average Remaining Life February 14, 2020 0.20 - - February 14, 2020 0.15 197,917 3.37 April 9, 2020 0.15 363,501 3.52 May 29, 2020 0.15 276,500 0.66 July 7, 2020 0.16 231,000 0.77 Balance at September 30, 2021 1,068,918 Cumulative warrant exercises as of the nine months ended September 30, 2021 were as follows: Warrant series Warrants exercised Amount Series A 21,677,084 $ 4,293,229 Series B 17,969,833 2,695,475 Series C 133,056,833 19,958,525 Series D 187,269,000 29,963,040 Subtotal 359,972,750 56,910,269 Common stock subscribed - (459,600 ) Total 359,972,750 $ 56,450,669

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and contingencies (Note 13)
13. Commitments and contingencies	13. Commitments and contingencies On May 10, 2018, the Company entered into a Development, Commercialization and Exclusive Distribution Agreement. As part of the agreement, the Company is required to make the following future milestone payments: ● 1 st ● 2 nd As of September 30, 2021, none of the future development milestones related to the above agreement have been met. The Company has assessed the probability of meeting the above milestones and has determined that an accrual is not necessary as of September 30, 2021, and December 31, 2020. From time to time, the Company may be exposed to claims and legal actions in the normal course of business. As of September 30, 2021, and continuing as of November 12, 2021, the Company is not aware of any pending or threatened material litigation claims against the Company. On September 20, 2021, Heska Corporation (“Heska”), Qorvo US, Inc. (“Qorvo US”), Qorvo Biotechnologies, LLC (“Qorvo Biotech” and, together with Qorvo US, “Qorvo”) and our company (collectively with Qorvo, the “Defendants”) entered into a settlement agreement pursuant to which the litigation previously commenced by Heska against the Defendants in the United States District Court for the Middle District of North Carolina, Case 1:19-cv-01108-LCB-JLW, was dismissed with prejudice. Pursuant to the settlement agreement, the parties also provided mutual releases of any and all claims related to the subject matter of the litigation. We were not required to make any payment or agree to any covenants restricting the conduct of our business in connection with the settlement.

Note 14 - Financial Instruments

Note 14 - Financial Instruments	9 Months Ended
	Sep. 30, 2021
Note 14 - Financial Instruments
14. Financial instruments	14. Financial instruments (a) Fair values The Company follows ASC topic 820, “Fair Value Measurements” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC topic 820 apply to other accounting pronouncements that require or permit fair value measurements. ASC topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date; and establishes a three level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. Inputs refers broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. To increase consistency and comparability in fair value measurements and related disclosures, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of the hierarchy are defined as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs for asset or liabilities. The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as of September 30, 2021 and December 31, 2020: September 30, 2021 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 4,464,874 $ - $ - $ - $ - $ 4,464,874 Lease obligations 112,343 114,589 115,713 115,713 1,018,607 1,476,965 $ 4,577,217 $ 114,589 $ 115,713 $ 115,713 $ 1,018,607 $ 5,941,839 December 31, 2020 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 1,248,628 $ - $ - $ - $ - $ 1,248,628 Debt obligations 527,360 - - - - 527,360 Lease obligations 59,662 62,463 64,356 66,307 1,087,998 1,340,786 $ 1,835,650 $ 62,463 $ 64,356 $ 66,307 $ 1,087,998 $ 3,116,774

Note 15 - Segment Information

Note 15 - Segment Information	9 Months Ended
	Sep. 30, 2021
15. Segment information	15. Segment information The Company’s operations comprise a single reportable segment engaged in the research, development targeting health and wellness solutions for the companion animal. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all the Company’s long-lived assets are in the United States of America (“US”). September 30, December 31, 2021 2020 Canada $ 172,945,051 $ 53,160,701 US 104,557,100 12,983,333 Total assest $ 277,502,151 $ 66,144,034 Total US property and equipment $ 706,266 $ 583,007 Total US right-of-use asset 1,419,790 1,318,716 $ 2,126,056 $ 1,901,723

Note 16 - Loss Per Share

Note 16 - Loss Per Share	9 Months Ended
	Sep. 30, 2021
Note 16 - Loss Per Share
16. Loss per share	16. Loss per share For the three months ended September 30 For the nine months ended September 30 2021 2020 2021 2020 Numerator Net loss for the period $ (6,345,687 ) $ (4,979,975 ) $ (15,093,178 ) $ (12,738,582 ) Charge to retained earnings for preferred share exchange - (32,038,603 ) - Loss attributable to common shareholders (6,345,687 ) (4,979,975 ) (47,131,781 ) (12,738,582 ) Denominator Weighted average shares - basic 978,494,076 550,541,878 948,664,410 291,314,002 Stock options - - - - Warrants - - - - Denominator for diluted loss per share 978,494,076 550,541,878 948,664,410 291,314,002 Loss per share - basic and diluted $ (0.01 ) $ (0.01 ) $ (0.05 ) $ (0.04 ) For the above‑mentioned periods, the Company had stock options and warrants outstanding which could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti‑dilutive.

Note 17 - Subsequent Events

Note 17 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Note 17 - Subsequent Events
17. Subsequent Events	17. Subsequent Events On October 1, 2021, Zomedica Inc., the wholly-owned subsidiary of Zomedica Corp. entered into a Stock Purchase Agreement with Branford PVT Mid-Hold, LLC pursuant to which Zomedica Inc. acquired 100% of the capital stock of Branford PVT Acquiror, Inc., a Delaware corporation “BPA”). BPA is a holding company whose direct and indirect wholly-owned subsidiaries include Georgia, United States-based Pulse Veterinary Technologies, LLC, which, together with its consolidated subsidiaries, is a leading provider of non-invasive shock wave therapy treatment devices to the veterinary industry. The purchase price for the Acquisition was $71.9 million in cash, which was subject to adjustments based on the amount of the Target’s cash and net working capital at the closing of the acquisition.

Note 3 - Significant Accounti_2

Note 3 - Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Note 3 - Significant Accounting Policies
Estimates and assumptions	Estimates and assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. The Company utilizes specific identification to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
Intangible Assets	Intangible Assets Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life.
Revenue recognition	Revenue recognition The Company enters into agreements which may contain multiple promises where customers purchase products, services or a combination thereof. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires judgment. We determine the transaction price for a contract based on the total consideration we expect to receive in exchange for the transferred goods or services. The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company’s contracts with customers are generally comprised of purchase orders for the sale of the point of care diagnostic instrument, consumable products, and warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The warranties are also a separate performance obligation, whereby revenue is recognized over time. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority. Accounts receivable are recorded at net realizable value and have payment terms of 30 days.
Cost of revenue	Cost of revenue Cost of goods sold consists of materials, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of goods sold.
Comparative figures	Comparative figures Certain prior year amounts have been reclassified to conform to the current year presentation. The change in presentation had no effect on the reported results of operations. Adjustments have been made to the consolidated balance sheets and consolidated statements of loss and comprehensive loss for three and six months ended September 30, 2020. These changes in classification do not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.

Note 4 - Prepaid Expenses, De_2

Note 4 - Prepaid Expenses, Deposits and Deferred Financing Costs (Tables)	9 Months Ended
	Sep. 30, 2021
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Schedule of Prepaid Expenses and Deposits	September 30, December 31, 2021 2020 Deposits (i) $ 1,256,094 $ 1,469,043 Prepaid marketing 64,300 26,330 Prepaid insurance 380,254 184,154 Other (ii) 101,218 62,211 Total $ 1,801,866 $ 1,741,738

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Note 5 - Property and Equipment
Schedule of Property and equipment	September 30, December 31, 2021 2020 Computer equipment $ 901,379 $ 364,165 Furniture and equipment 110,244 121,281 Laboratory equipment 225,330 234,087 Leasehold improvements 275,149 571,460 1,512,102 1,290,993 Accumulated depreciation and amortization 805,836 707,986 Net property and equipment $ 706,266 $ 583,007

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Note 6 - Intangible Assets
Schedule of Finite-Lived Intangible Assets	September 30, December 31, 2021 2020 Computer software 28,097 $ 22,882 Trademarks 16,236 16,236 Website 755,968 513,680 800,301 552,798 Accumulated amortization 326,335 190,135 Net intangibles $ 473,966 $ 362,663

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Note 7 - Leases
Schedule of Lessee, Operating Lease, Right of Use Asset and Lease Liabilities	September 30, 2021 December 31, 2020 Right-of-use asset Cost Aggregate lease commitments $ 1,778,798 $ 2,067,505 Less: impact of present value and lease modification (154,695 ) (513,894 ) Balance 1,624,103 1,553,611 Reduction in right-of-use asset Straight line amortization 232,214 379,043 Interest (27,901 ) (144,148 ) Balance 204,313 234,895 Net book value $ 1,419,790 $ 1,318,716 Lease liabilities Additions $ 1,647,449 $ 1,553,611 Payments (198,385 ) (356,972 ) Interest 27,901 144,147 Total lease liabilities $ 1,476,965 $ 1,340,786 Current portion of lease liabilities 407,278 252,788 Long term portion of lease liabilities 1,069,687 1,087,998 Total lease liabilities $ 1,476,965 $ 1,340,786
Schedule of Lessee, Operating Lease, Liability, Maturity	2021 - remainder balance $ 112,342 $ 400,133 2022 461,727 412,137 2023 475,579 424,501 2024 489,845 437,236 2025 40,920 36,526 Total $ 1,580,413 $ 1,710,533

Note 9 - Preferred Shares (Tabl

Note 9 - Preferred Shares (Tables)	9 Months Ended
	Sep. 30, 2021
Note 9 - Preferred Stock
Schedule of Preferred Stock	Number of Preferred preferred stock stock amount Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 11,961,397 Stock exchanged (12 ) (11,961,397 ) Balance at September 30, 2021 - $ -

Note 11 - Stockbased Compensati

Note 11 - Stockbased Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Note 11 - Stock-based Compensation
Schedule of Share-based Payment Arrangement, Option, Activity	Number of Options Weighted Avg Exercise Price Balance at December 31, 2020 39,604,515 $ 0.36 Stock options granted 12,100,000 $ 0.86 Stock options exercised 7,017,776 $ 0.25 Unvested stock options forfeited 1,670,000 $ 0.64 Vested stock options exprired 4,034,015 $ 1.52 Balance at September 30, 2021 38,982,724 $ 0.40 Vested at September 30, 2021 9,152,474 $ 0.28
Schedule of Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) March 14, 2020 0.19 3,028,557 1,675,807 1,352,750 3.45 July 9, 2020 0.18 175,000 87,500 87,500 3.78 August 25, 2020 0.13 20,000 - 20,000 3.90 September 29, 2020 0.11 225,000 225,000 - 4.00 October 1, 2020 0.11 266,667 41,667 225,000 4.01 October 20, 2020 0.09 25,000 10,000 15,000 4.06 December 31, 2020 0.23 24,142,500 6,762,500 17,380,000 4.25 February 26, 2021 1.87 600,000 150,000 450,000 4.41 March 1, 2021 2.06 200,000 50,000 150,000 4.42 March 8, 2021 1.88 200,000 50,000 150,000 4.44 March 15, 2021 2.49 200,000 50,000 150,000 4.46 May 12, 2021 0.78 3,800,000 - 3,800,000 4.62 May 14, 2021 0.75 3,200,000 50,000 3,150,000 4.62 August 11, 2021 0.57 1,300,000 - 1,300,000 4.87 August 18, 2021 0.50 200,000 - 200,000 4.88 August 23, 2021 0.50 100,000 - 100,000 4.90 September 13,2021 0.57 800,000 - 800,000 4.96 September 27,2021 0.54 500,000 - 500,000 4.99 Balance at September 30, 2021 38,982,724 9,152,474 29,830,250
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	February 26, 2021 March 1, 2021 March 8, 2021 March 15, 2021 Volatility 117 % 117 % 117 % 117 % Risk-free interest rate 0.95 % 0.92 % 1.07 % 1.06 % Expected life 10 years 10 years 10 years 10 years Dividend yield 0 % 0 % 0 % 0 % Common share price $ 1.87 $ 2.06 $ 1.88 $ 2.49 Strike price $ 1.87 $ 2.06 $ 1.88 $ 2.49 Forfeiture rate zero zero zero zero May 12, 2021 August 11, 2021 August 23, 2021 September 13, 2021 Volatility 118 % 116 % 116 % 116 % Risk-free interest rate 1.11 % 0.96 % 0.92 % 0.96 % Expected life 6.21 - 6.22 Years 6.18 - 6.25 6.25 6.25 Dividend yield 0 % 0 % 0 % 0 % Common share price $ 0.78 $ 0.56 $ 0.50 $ 0.57 Strike price $ 0.78 $ 0.57 $ 0.50 $ 0.57 Forfeiture rate zero zero zero zero September 27, 2021 Volatility 116 % Risk-free interest rate 1.14 % Expected life 6.25 Dividend yield 0 % Common share price $ 0.54 Strike price $ 0.54 Forfeiture rate zero

Note 12 - Warrants (Tables)

Note 12 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Note 12 - Warrants
Schedule of Warrants Outstanding	Original Issue date Exercise Price Warrants Outstanding Weighted Average Remaining Life February 14, 2020 0.20 - - February 14, 2020 0.15 197,917 3.37 April 9, 2020 0.15 363,501 3.52 May 29, 2020 0.15 276,500 0.66 July 7, 2020 0.16 231,000 0.77 Balance at September 30, 2021 1,068,918
Schedule of Cumulative Warrant Exercises	Warrant series Warrants exercised Amount Series A 21,677,084 $ 4,293,229 Series B 17,969,833 2,695,475 Series C 133,056,833 19,958,525 Series D 187,269,000 29,963,040 Subtotal 359,972,750 56,910,269 Common stock subscribed - (459,600 ) Total 359,972,750 $ 56,450,669

Note 14 - Financial Instrumen_2

Note 14 - Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Note 14 - Financial Instruments
Schedule of Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities	September 30, 2021 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 4,464,874 $ - $ - $ - $ - $ 4,464,874 Lease obligations 112,343 114,589 115,713 115,713 1,018,607 1,476,965 $ 4,577,217 $ 114,589 $ 115,713 $ 115,713 $ 1,018,607 $ 5,941,839 December 31, 2020 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 1,248,628 $ - $ - $ - $ - $ 1,248,628 Debt obligations 527,360 - - - - 527,360 Lease obligations 59,662 62,463 64,356 66,307 1,087,998 1,340,786 $ 1,835,650 $ 62,463 $ 64,356 $ 66,307 $ 1,087,998 $ 3,116,774

Note 15 - Segment Information (

Note 15 - Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Note 15 - Segment Information (Tables)
Schedule of Long-lived Schedule of Assets by Geographic Areas	September 30, December 31, 2021 2020 Canada $ 172,945,051 $ 53,160,701 US 104,557,100 12,983,333 Total assest $ 277,502,151 $ 66,144,034 Total US property and equipment $ 706,266 $ 583,007 Total US right-of-use asset 1,419,790 1,318,716 $ 2,126,056 $ 1,901,723

Note 16 - Loss Per Share (Table

Note 16 - Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Note 16 - Loss Per Share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the three months ended September 30 For the nine months ended September 30 2021 2020 2021 2020 Numerator Net loss for the period $ (6,345,687 ) $ (4,979,975 ) $ (15,093,178 ) $ (12,738,582 ) Charge to retained earnings for preferred share exchange - (32,038,603 ) - Loss attributable to common shareholders (6,345,687 ) (4,979,975 ) (47,131,781 ) (12,738,582 ) Denominator Weighted average shares - basic 978,494,076 550,541,878 948,664,410 291,314,002 Stock options - - - - Warrants - - - - Denominator for diluted loss per share 978,494,076 550,541,878 948,664,410 291,314,002 Loss per share - basic and diluted $ (0.01 ) $ (0.01 ) $ (0.05 ) $ (0.04 )

Prepaid expenses, deposits, and

Prepaid expenses, deposits, and deferred financing costs (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Note 10 - Common Stock
Deposits	$ 1,256,094	$ 1,469,043
Prepaid marketing	64,300	26,330
Prepaid insurance	380,254	184,154
Other	101,218	62,211
Total	$ 1,801,866	$ 1,741,738

Prepaid expenses, deposits, a_2

Prepaid expenses, deposits, and deferred financing costs (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Note 10 - Common Stock
Prepaid Expenses and Deposits, Noncurrent	$ 168,020	$ 13,924

Property and equipment (Details

Property and equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property and equipment, gross	$ 1,512,102	$ 1,290,993
Accumulated depreciation and amortization	805,836	707,986
Net property and equipment	706,266	583,007
Computer Equipment [Member]
Property and equipment, gross	901,379	364,165
Furniture and Fixtures [Member]
Property and equipment, gross	110,244	121,281
Laboratory Equipment [Member]
Property and equipment, gross	225,330	234,087
Leasehold Improvements [Member]
Property and equipment, gross	$ 275,149	$ 571,460

Property and equipmentt (Detail

Property and equipmentt (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Note 1 - Nature of Operations
Depreciation, Total	$ 60,445	$ 78,200	$ 175,168	$ 232,475

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accumulated amortization	$ 326,335	$ 190,135
Finite-lived intangible assets, gross	800,301	552,798
Net intangibles	473,966	362,663
Trademarks [Member]
Finite-lived intangible assets, gross	16,236	16,236
Computer Software [Member]
Finite-lived intangible assets, gross	28,097	22,882
Website [Member]
Finite-lived intangible assets, gross	$ 755,968	$ 513,680

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Note 6 - Intangible Assets
Amortization of Intangible Assets, Total	$ 46,732	$ 45,399	$ 136,200	$ 177,873

Leases (Details)

Leases (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Leases (Details)
Total lease liabilities	$ 1,476,965	$ 1,340,786
Long term portion of lease liabilities	1,069,687	1,087,998
Current portion of lease liabilities	407,278	252,788
Additions	1,647,449	1,553,611
Payments	(198,385)	(356,972)
Interest	27,901	144,147
Straight line amortization	232,214	379,043
Interest	(27,901)	(144,148)
Total lease liabilities	1,476,965	1,340,786
Reduction in right-of-use asset, balance	204,313	234,895
Net book value	1,419,790	1,318,716
Aggregate lease commitments	1,778,798	2,067,505
Less: impact of present value and lease modification	154,695	513,894
Cost, balance	$ 1,624,103	$ 1,553,611

Leases (Details 1)

Leases (Details 1) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Leases (Details)
Total	$ 1,580,413	$ 1,710,533
2025	40,920	36,526
2024	489,845	437,236
2023	475,579	424,501
2022	461,727	412,137
2021 - remainder balance	$ 112,342	$ 400,133

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 15, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Operating Lease, Right-of-Use Asset		$ 1,419,790		$ 1,419,790		$ 1,318,716
Increase (Decrease) in Prepaid Rent				0	$ 1,002,113
Lease Agreement with Wickfield Phoenix LLC [Member]
Operating Lease, Expense		$ 93,980	$ 103,375	270,554	279,997
Lessee, Operating Lease, Term of Contract (Month)	41 months
Common area maintenance charges				3,882
Monthly Rent Payment	$ 10,009
Lessee, Operating Lease, Discount Rate	3.95%
Gain (loss) on Operating Lease, Right-of-Use Assets	$ 365,840
Lease Agreement with Wickfield Phoenix LLC [Member] | Minimum [Member]
Monthly Rent Payment	$ 4,580			$ 32,452
Lease Agreement with Wickfield Phoenix LLC [Member] | February 1, 2020 [Member]
Lessee, Operating Lease, Term of Contract (Month)				60 months
Monthly Rent Payment				$ 36,525
Lessee, Operating Lease, Discount Rate		12.00%		12.00%
Operating Lease, Right-of-Use Asset		$ 1,553,611		$ 1,553,611
Lease Agreement with Wickfield Phoenix LLC [Member] | February 1, 2021 [Member]
Lessee, Operating Lease, Term of Contract (Month)				48 months
Monthly Rent Payment				$ 30,911
Lessee, Operating Lease, Discount Rate		3.95%		3.95%
Gain (loss) on Operating Lease, Right-of-Use Assets				$ 731
Operating Lease, Right-of-Use Asset, Lease Modification		$ 1,258,263		1,258,263
Operating Lease, Liability, Total		1,281,609		1,281,609
Lease Agreement with Wickfield Phoenix LLC [Member] | February 1, 2021 [Member] | Minimum [Member]
Monthly Rent Payment				12,039
Lease Agreement with Wickfield Phoenix LLC [Member] | Research and Development Expense [Member]
Operating Lease, Expense		31,605	17,229	69,403	56,221
Lease Agreement with Wickfield Phoenix LLC [Member] | General and Administrative Expense [Member]
Operating Lease, Expense		62,375	$ 86,146	201,151	$ 223,776
Lease Modification [Member]
Gain (loss) on Operating Lease, Right-of-Use Assets				(59,097)
Lease Cancellation [Member]
Operating Lease, Right-of-Use Asset, Lease Cancellation		$ 1,061,210		1,061,210
Increase (Decrease) in Prepaid Rent				$ 1,002,113

Loan arrangements (Details Narr

Loan arrangements (Details Narrative) - USD ($)	Jun. 13, 2021	Apr. 30, 2020	Mar. 27, 2020	Oct. 18, 2017	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Emergency economic relief			$ 2,000,000,000,000
Temporarily guarantee loans description			The Program provides for 100% federally guaranteed loans to small businesses to allow employers to keep workers employed and maintain payroll during the pandemic and economic downturn. Under the Program, qualified companies are eligible for a loan in an amount equal to the lesser of $10 million or 2.5x the business’s average monthly payroll
Proceeds from Short-term Debt, Total		$ 527,360
Gain (Loss) on Extinguishment of Debt, Total					$ 0	$ 0	$ (533,414)	$ 0
Loan Arrangement With Shareholder [Member]
Debt Instrument, Interest Rate, Stated Percentage				14.00%
Debt Instrument, Term (Year)				5 years
Debt Agreement, Maximum Borrowing Capacity				$ 5,000,000
Debt Agreement, Minimum Borrowing Per Advances				$ 250,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Short-term Debt, Total		$ 527,360
Gain (Loss) on Extinguishment of Debt, Total	$ 533,414
Gain (Loss) on Extinguishment of Debt, Portion Attributable to Accrued Interest	$ 6,054

Preferred shares (Details)

Preferred shares (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance, amount		$ 11,961,397
Series Preferred Shares [Member]
Balance, number (in shares)	0	12	12
Balance, amount	$ 11,961,397	$ 11,961,397	$ 11,961,397
Stock redemption (in shares)	(12)
Stock redemption	$ (11,961,397)

Preferred shares (Details Narra

Preferred shares (Details Narrative) - USD ($)	Mar. 07, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Charge to retained earnings for preferred share exchange		$ 0	$ (32,038,603)	$ 0
Conversion of Stock, Amount Issued			$ 11,961,397
Preferred Stock, Stated Value Per Share (in dollars per share)					$ 11,961,397
Series 1 Preferred Shares [Member]
Preferred Stock, Shares Authorized (in shares)		20	20
Net Sales Payments, Percentage of Sales		9.00%	9.00%
Fundamental transaction description			defined to include an amalgamation, merger or other business combination transaction involving our company in which the shareholders do not have the right to cast more than 50% of the votes that may be cast for the election of directors, or a sale, lease or other disposition of the properties and/or assets of our company as an entirety or substantially as an entirety to a third party), the holders of the Series 1 Preferred Shares will be entitled to receive consideration for their Series 1 Preferred Shares equal to a multiple of the stated value of the Series 1 Preferred Shares ranging from 5.0 to 9.0 depending on the timing of the fundamental transaction
Preferred Stock, Stated Value Per Share (in dollars per share)		$ 1,000,000	$ 1,000,000
Redemption of Preferred Shares for Common Shares [Member]
Conversion of Stock, Amount Issued	$ 44,000,000
Conversion of Stock, Shares Issued (in shares)	24,719,101

Common shares (Details Narrativ

Common shares (Details Narrativel) - USD ($)	Feb. 08, 2021	Jul. 07, 2020	Apr. 09, 2020	Jun. 30, 2020	May 29, 2020	Feb. 29, 2020	Feb. 14, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 0.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							20,833,334
Proceeds from Issuance of Common Stock									$ 199,525,000	$ 56,496,283
Class of Warrant or Right, Issued During Period (in shares)							20,833,334
Class of Warrant or Right, Issued During Period, Value							$ 794,345
Class of Warrant or Right, Period Exerciseable (Month)							6 months
Issuance of Common Shares and Warrants, Direct Costs of Issuance	$ 14,281,368	$ 2,268,215	$ 582,977		$ 1,908,202	$ 348,220			(14,280,914)
Stock Issued During Period, Shares, Exercise of Warrants and Pre-funded Warrants (in shares)				12,162,492
Adjustments to Equity, Warrant Issued								$ 0		$ 0
Common Stocks [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance		1,224,218	428,283		1,088,876	238,217			$ (14,280,914)
Stock Issued During Period, Value, New Issues	199,525,000
Additional Paid-in Capital [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance		1,043,997	154,694		$ 819,327	110,003
Public Offering [Member]
Proceeds from Issuance of Common Stock			2,942,248
Stock Issued During Period, Shares, New Issues (in shares)					121,163,333
Proceeds from Issuance or Sale of Equity, Total		29,997,500	$ 4,000,000		$ 19,998,783
Stock Issued During Period, Value, New Issues		$ 16,290,941			$ 11,336,422
Offering Price (in dollars per share)			$ 0.12
Shares Issued, Number of Common Shares Per Share (in shares)		1	1
Shares Issued, Number of Warrants Per Share (in shares)			$ 0.5
Stock and Warrants Issued During Period, Shares, New Issues (in shares)			33,333,334
The Common Shares Offering [Member]
Proceeds from Issuance of Common Stock	$ 199,525,000
Stock Issued During Period, Shares, New Issues (in shares)	91,315,790
Shares Issued, Price Per Share (in dollars per share)	$ 1.90
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)							20,833,334
Proceeds from Issuance or Sale of Equity, Total							$ 2,500,000
Stock Issued During Period, Value, New Issues							$ 1,705,655
Shares Issued, Number of Common Shares Per Share (in shares)							1
Shares Issued, Price Per Share (in dollars per share)							$ 0.12
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	13,697,368
Public Offering with One Common Share and One Series C Warrant [Member]
Offering Price (in dollars per share)					$ 0.15
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15				$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,666,667				1,041,667
Class of Warrant or Right, Issued During Period (in shares)			1,666,667				1,041,667
Adjustments to Equity, Warrant Issued			$ 161,714			52,496
Placement Agent Warrants [Member] | Common Stocks [Member]
Adjustments to Equity, Warrant Issued			118,951			35,816
Placement Agent Warrants [Member] | Additional Paid-in Capital [Member]
Adjustments to Equity, Warrant Issued			$ 42,763			$ 16,680
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			16,666,667
Class of Warrant or Right, Issued During Period (in shares)			16,666,667
Proceeds from Issuance of Warrants			$ 1,057,752
Pre-funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001			$ 0.0001
Class of Warrant or Right, Issued During Period (in shares)					12,170,000
Proceeds from Issuance of Warrants		$ 2,329,983			$ 1,080,289
Series C Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					133,333,333
Class of Warrant or Right, Issued During Period (in shares)					133,333,333
Proceeds from Issuance of Warrants					$ 7,582,072
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					1
Series D Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.1599
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		187,500,000
Class of Warrant or Right, Issued During Period (in shares)		25,000,000
Proceeds from Issuance of Warrants		$ 11,376,575
Stock Issued During Period, Shares, New Issues (in shares)		162,500,000
Public Offering with One Pre-funded Warrant and One Series C Warrant [Member]
Offering Price (in dollars per share)					$ 0.1499

Stockbased Compensation Issuanc

Stockbased Compensation Issuance of Stock Options (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Number of Options, Options Outstanding (in shares)			39,604,515
Weighted Avg Exercise Price, Options Outstanding (in dollars per share)			$ 0.36
Number of Options, Stock options granted (in shares)	2,900,000	515,000	12,100,000	7,571,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)			$ 0.86
Stock options exercised (in shares)			7,017,776
Weighted Avg Exercise Price, Stock options exercised (in dollars per share)			$ 0.25
Number of Options, Stock options forfeited (in shares)			1,670,000
Weighted Avg Exercise Price, Stock options forfeited (in dollars per share)			$ 0.64
Number of Options, Stock options cancelled (in shares)			4,034,015
Weighted Avg Exercise Price, Stock options cancelled (in dollars per share)			$ 1.52
Number of Options, Options Outstanding (in shares)	38,982,724		38,982,724
Weighted Avg Exercise Price, Options Outstanding (in dollars per share)	$ 0.40		$ 0.40
Number of Options, Options Vested (in shares)	9,152,474		9,152,474
Weighted Avg Exercise Price, Vested (in dollars per share)	$ 0.28		$ 0.28

Stockbased Compensation Details

Stockbased Compensation Details of the Issued Stock Options (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Number of Options (in shares)	38,982,724	39,604,515
Number of Options, Options Vested (in shares)	9,152,474
Number of unvested options outstanding (in shares)	29,830,250
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.86
March 14, 2020 [Member] | Options 1 [Member]
Number of Options (in shares)	3,028,557
Number of unvested options outstanding (in shares)	1,352,750
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.19
Number of Vested Options (in shares)	1,675,807
Weighted Avg Remaining Life (Year)	3 years 5 months 12 days
July 9, 2020 [Member] | Options 2 [Member]
Number of Options (in shares)	175,000
Number of unvested options outstanding (in shares)	87,500
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.18
Number of Vested Options (in shares)	87,500
Weighted Avg Remaining Life (Year)	3 years 9 months 10 days
August 25, 2020 [Member] | Options 3 [Member]
Number of Options (in shares)	20,000
Number of unvested options outstanding (in shares)	20,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.13
Number of Vested Options (in shares)	0
Weighted Avg Remaining Life (Year)	3 years 10 months 24 days
September 29, 2020 [Member] | Options 4 [Member]
Number of Options (in shares)	225,000
Number of unvested options outstanding (in shares)	0
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.11
Number of Vested Options (in shares)	225,000
Weighted Avg Remaining Life (Year)	4 years
October 1, 2020 [Member] | Option 5 [Member]
Number of Options (in shares)	266,667
Number of unvested options outstanding (in shares)	225,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.11
Number of Vested Options (in shares)	41,667
Weighted Avg Remaining Life (Year)	4 years 3 days
October 20, 2020 [Member] | Option 6 [Member]
Number of Options (in shares)	25,000
Number of unvested options outstanding (in shares)	15,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.09
Number of Vested Options (in shares)	10,000
Weighted Avg Remaining Life (Year)	4 years 21 days
December 31, 2020 [Member] | Option 7 [Member]
Number of Options (in shares)	24,142,500
Number of unvested options outstanding (in shares)	17,380,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.23
Number of Vested Options (in shares)	6,762,500
Weighted Avg Remaining Life (Year)	4 years 3 months
February 26, 2021 [Member] | Options 16 [Member]
Number of Options (in shares)	60,000,000,000
Number of Options, Options Vested (in shares)	1,500,000,000
Number of unvested options outstanding (in shares)	4,500,000,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 1.87
Weighted Avg Remaining Life (Year)	4 years 4 months 28 days
March 1, 2021 [Member] | Option 8 [Member]
Number of Options (in shares)	200,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 2.06
Number of Vested Options (in shares)	50,000
Weighted Avg Remaining Life (Year)	4 years 5 months 1 day
March 8, 2021 [Member] | Option 9 [Member]
Number of Options (in shares)	200,000
Number of Options, Options Vested (in shares)	50,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 1.88
Weighted Avg Remaining Life (Year)	4 years 5 months 8 days
March 15, 2021 [Member] | Option 10 [Member]
Number of Options (in shares)	200,000
Number of Options, Options Vested (in shares)	50,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 2.49
Weighted Avg Remaining Life (Year)	4 years 5 months 15 days
May 12, 2021 [Member] | Option 11 [Member]
Number of Options (in shares)	3,800,000
Number of Options, Options Vested (in shares)	0
Number of unvested options outstanding (in shares)	3,800,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.78
Weighted Avg Remaining Life (Year)	4 years 7 months 13 days
May 14, 2021 [Member] | Option 12 [Member]
Number of Options (in shares)	3,200,000
Number of Options, Options Vested (in shares)	50,000
Number of unvested options outstanding (in shares)	3,150,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.75
Weighted Avg Remaining Life (Year)	4 years 7 months 13 days
August 11, 2021 [Member] | Options 13 [Member]
Number of Options (in shares)	1,300,000
Number of Options, Options Vested (in shares)	0
Number of unvested options outstanding (in shares)	1,300,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.57
Weighted Avg Remaining Life (Year)	4 years 10 months 13 days
August 18, 2021 [Member] | Options 14 [Member]
Number of Options (in shares)	200,000
Number of Options, Options Vested (in shares)	0
Number of unvested options outstanding (in shares)	200,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.50
Weighted Avg Remaining Life (Year)	4 years 10 months 17 days
August 23, 2021 [Member] | Options 15 [Member]
Number of Options (in shares)	100,000
Number of Options, Options Vested (in shares)	0
Number of unvested options outstanding (in shares)	100,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.50
Weighted Avg Remaining Life (Year)	4 years 10 months 24 days
September 13, 2021 [Member] | Options 16 [Member]
Number of Options (in shares)	800,000
Number of Options, Options Vested (in shares)	0
Number of unvested options outstanding (in shares)	800,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.57
Weighted Avg Remaining Life (Year)	4 years 11 months 15 days
September 13, 2021 [Member] | Options 17 [Member]
Number of Options (in shares)	500,000
Number of Options, Options Vested (in shares)	0
Number of unvested options outstanding (in shares)	500,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.54
Weighted Avg Remaining Life (Year)	4 years 11 months 26 days

Stockbased Compensation Valuati

Stockbased Compensation Valuation Assumptions for Fair Value of Options Granted (Details) - $ / shares	Sep. 13, 2021	Aug. 11, 2021	May 12, 2021	Mar. 15, 2021	Mar. 08, 2021	Mar. 02, 2021	Sep. 27, 2021	Aug. 23, 2021	Feb. 26, 2021	Mar. 01, 2021
Volatility				117.00%	117.00%	117.00%			117.00%
Risk-free interest rate				1.06%	1.07%	0.92%			0.95%
Expected life (years) (Year)				10 years	10 years	10 years			10 years
Dividend yield				0.00%	0.00%	0.00%			0.00%
Common share price (in dollars per share)				$ 2.49	$ 1.88				$ 1.87	$ 2.06
Strike price (in dollars per share)				$ 2.49	$ 1.88				$ 1.87	$ 2.06
Forfeiture rate				0.00%	0.00%	0.00%			0.00%
Options 1 [Member]
Volatility	116.00%						116.00%	116.00%
Risk-free interest rate	0.96%						1.14%	0.92%
Expected life (years) (Year)	6 years 3 months						6 years 3 months	6 years 3 months
Dividend yield	0.00%						0.00%	0.00%
Common share price (in dollars per share)	$ 0.57						$ 0.54	$ 0.50
Strike price (in dollars per share)	$ 0.57						$ 0.54	$ 0.50
Forfeiture rate	0.00%						0.00%	0.00%
Options 2 [Member]
Volatility		116.00%	118.00%
Risk-free interest rate		0.96%	1.11%
Dividend yield		0.00%	0.00%
Common share price (in dollars per share)		$ 0.56	$ 0.78
Strike price (in dollars per share)		$ 0.57	$ 0.78
Forfeiture rate		0.00%	0.00%
Options 2 [Member] | Minimum [Member]
Expected life (years) (Year)		6 years 2 months 4 days	6 years 2 months 15 days
Options 2 [Member] | Maximum [Member]
Expected life (years) (Year)		6 years 3 months	6 years 2 months 19 days

Stockbased Compensation (Detail

Stockbased Compensation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Share-based Payment Arrangement, Expense	$ 1,437,778	$ 187,969	$ 4,502,597	$ 478,835
Proceeds from Stock Options Exercised	$ 400,208		$ 1,768,010	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			4 years	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	2,900,000	515,000	12,100,000	7,571,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			10 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	1,787,175		7,017,776
Stock Issued During Period, Value, Stock Options Exercised	$ 400,208		$ 1,768,010

Warrants - Details of Outstandi

Warrants - Details of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Feb. 14, 2020
Warrants and Rights, Outstanding (in shares)	1,068,918
Warrant, exercise price (in dollars per share)		$ 0.20
Warrant One [Member]
Warrants and Rights, Outstanding (in shares)	0
Warrant, exercise price (in dollars per share)	$ 0.20
Warrant Two [Member]
Warrants and Rights, Outstanding (in shares)	197,917
Warrant, exercise price (in dollars per share)	$ 0.15
Warrants, weighted average remaining life (Year)	3 years 4 months 13 days
Warrant Three [Member]
Warrants and Rights, Outstanding (in shares)	363,501
Warrant, exercise price (in dollars per share)	$ 0.15
Warrants, weighted average remaining life (Year)	3 years 6 months 7 days
Warrant Four [Member]
Warrants and Rights, Outstanding (in shares)	276,500
Warrant, exercise price (in dollars per share)	$ 0.15
Warrants, weighted average remaining life (Year)	7 months 28 days
Warrant Five [Member]
Warrants and Rights, Outstanding (in shares)	231,000
Warrant, exercise price (in dollars per share)	$ 0.16
Warrants, weighted average remaining life (Year)	9 months 7 days

Warrants - Cumulative Warrant E

Warrants - Cumulative Warrant Exercises (Details)	9 Months Ended
	Sep. 30, 2021USD ($)shares
Total warrant execised | shares	359,972,750
Total Amount	$ 56,450,669
Common stock subscribed amount	$ (459,600)
Sub Total Warrent exercised shares | shares	359,972,750
Sub Total Warrent amount	$ 56,910,269
Series A Warrants [Member]
Sub Total Warrent exercised shares | shares	21,677,084
Sub Total Warrent amount	$ 4,293,229
Series B Warrants [Member]
Sub Total Warrent exercised shares | shares	17,969,833
Sub Total Warrent amount	$ 2,695,475
Series C Warrants [Member]
Sub Total Warrent exercised shares | shares	133,056,833
Sub Total Warrent amount	$ 19,958,525
Series D Warrants [Member]
Sub Total Warrent exercised shares | shares	187,269,000
Sub Total Warrent amount	$ 29,963,040

Warrants (Details Narrative)

Warrants (Details Narrative) - $ / shares	Jul. 07, 2020	Apr. 09, 2020	May 29, 2020	Feb. 14, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Series A Warrants [Member]
Warrants and Rights Outstanding, Term (Year)				5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15		$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,666,667		1,041,667
Series B Warrants [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		16,666,667
Series C Warrants [Member]
Warrants and Rights Outstanding, Term (Year)			2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			133,333,333
Series C Pre-funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			12,170,000
Series D Warrants [Member]
Warrants and Rights Outstanding, Term (Year)	2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.1599
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	187,500,000
Series D Pre-funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	25,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Seraph Biosciences, Inc. [Member]	May 10, 2018USD ($)
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Cash	$ 3,500,000
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Equity	$ 3,500,000

Financial Instruments Contractu

Financial Instruments Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Accounts payable and accrued liabilities	$ 4,464,874	$ 1,248,628
Debt obligations		527,360
Total lease liabilities	1,476,965	1,340,786
Liabilities, Total	5,941,839	3,116,774
Accounts payable and Accrued Liabilities, maturity less than 3 Months	4,464,874	1,248,628
Lease obligations, maturity less than 3 Months	112,343	59,662
Maturity Less Than 3 Months	4,577,217	1,835,650
Accounts payable and accrued liabilities, Maturity 3 to 6 Months	0	0
Lease obligations, Maturity 3 to 6 Months	114,589	62,463
Maturity 3 to 6 Months	114,589	62,463
Accounts payable and accrued liabilities, Maturity 6 to 9 Months	0	0
Lease obligations, Maturity 6 to 9 Months	115,713	64,356
Maturity 6 to 9 Months	115,713	64,356
Accounts payable and accrued liabilities, Maturity 9 to 12 Months	0
Lease obligations, Maturity 9 to 12 Months	115,713	66,307
Maturity 9 to 12 Months	115,713	66,307
Accounts payable and accrued liabilities, Greater than 1 Year	0	0
Long term portion of lease liabilities Greater than 1 year	1,018,607	1,087,998
Maturity Greater Than 1 Year	$ 1,018,607	1,087,998
Debt obligations, Maturity less than 3 Months		527,360
Debt obligations, Maturity 3 to 6 Months		0
Debt obligations, Maturity 6 to 9 Months		0
Debt obligations, Maturity 9 to 12 Months		0
Debt obligations, Maturity Greater Than 1 Year		$ 0

Segment Information Longlived A

Segment Information Longlived Assets by Geographic Areas (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Assets	$ 277,502,151	$ 66,144,034
Total US Property and equipment, net	706,266	583,007
Total US Right-of-use asset	1,419,790	1,318,716
Property, Plant and Equipment, Including Leased Assets	2,126,056	1,901,723
CANADA
Assets	172,945,051	53,160,701
US
Assets	$ 104,557,100	$ 12,983,333

Loss Per Share Loss Per Share (

Loss Per Share Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Net loss	$ (6,345,687)	$ (4,979,975)	$ (15,093,178)	$ (12,738,582)
Charge to retained earnings for preferred share exchange	0		(32,038,603)	0
Loss attributable to common shareholders	$ (6,345,687)	$ (4,979,975)	$ (47,131,781)	$ (12,738,582)
Weighted average shares - basic (in shares)	978,494,076	550,541,878	948,664,410	291,314,002
Stock options (in shares)	0	0	0	0
Warrants (in shares)	0	0	0	0
Denominator for diluted loss per share (in shares)	978,494,076	550,541,878	948,664,410	291,314,002
Loss per share - basic and diluted (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.05)	$ (0.04)

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] $ in Millions	Oct. 01, 2021USD ($)
Purchase price for acquisition in cash	$ 71.9
Qwnership interest percentage rate	100.00%